|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We used qRT-PCR assay to quantify mRNA levels of ATM gene in 454 breast tumours from patients with known clinical/pathological status and outcome; reverse phase protein arrays (RPPA) were used to assess the levels of ATM and 14 proteins in 233 breast tumours.
|
25742469 |
2015 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Our findings provide the first experimental evidence that ATM is a human breast tumor suppressor.
|
20177072 |
2010 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Fifty-two breast tumors from 51 patients, 38 of them with concomitant in situ component (CIS), were analyzed by immunohistochemistry for the expression of ATM.
|
16329039 |
2006 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Loss of heterozygosity at the ATM locus has been reported in 30-40% of breast tumours and 50-70% show altered ATM protein levels.
|
16112413 |
2005 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We also studied breast tumors from ATM mutants, and three showed retention of both alleles, whereas the fourth showed loss of the mutant allele.
|
9537233 |
1998 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We screened a cohort of 173 nonselected primary breast tumors for LOH in a 4 cM region at 11q23 spanning the ATM gene.
|
11793440 |
2002 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Loss of heterozygosity (LOH) in the ATM region of chromosome 11q23.1 showed that the normal ATM allele was lost in the breast tumor of the older sister.
|
10571946 |
1999 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
So far, no clear histopathological and molecular features of breast tumours occurring in ATM deleterious variant carriers have been described, but identification of an ATM-associated tumour signature may help in patient management.
|
29665859 |
2018 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Analysis of loss of heterozygosity (LOH) in 18 breast tumors from women carrying likely pathogenic rare sequence variants revealed no consistent pattern of loss of the ATM variant.
|
21787400 |
2011 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
To investigate whether aberrant methylation of the ATM promoter or loss of the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) may be the underlying causes of reduced ATM protein levels often seen in breast tumours.
|
17593081 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The analysis of additional breast tumors from ten BC families in which a germline ATM mutation had been identified revealed a high frequency of wild-type allele loss.
|
28691344 |
2017 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation.
|
8665503 |
1996 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
These findings indicate that epigenetic silencing of ATM expression occurs in locally advanced breast tumors, and establish a link at the molecular level between reduced ATM function and sporadic breast malignancy.
|
15516988 |
2004 |
|
Mammary Neoplasms
|
0.500 |
CausalMutation
|
group |
CLINVAR |
|
|
|
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
|
|
|
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
ATM variants and cancer risk in breast cancer patients from Southern Finland.
|
16914028 |
2006 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer.
|
18264724 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Dominant negative ATM mutations in breast cancer families.
|
11830610 |
2002 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
We have found that carriers of an ATM missense mutation, who were treated with radiotherapy for the first breast tumour, developed their second tumour on average in a 92-month interval compared to a 136-month mean interval for those CBC patients who neither received RT nor carried a germline variant, (p = 0.029).
|
17393301 |
2008 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer.
|
17166884 |
2007 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls.
|
11996792 |
2002 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Two ATM variants and breast cancer risk.
|
15880680 |
2005 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Consortium piecing together role of ATM gene in breast cancer.
|
11830600 |
2002 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Contributions of ATM mutations to familial breast and ovarian cancer.
|
12810666 |
2003 |
|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
LHGDN |
Cancer risks and mortality in heterozygous ATM mutation carriers.
|
15928302 |
2005 |